S. Marubayashi

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Eric Vangrevelinghe, Andrew L. Kung, James E. Bradner, 2011, The Journal of experimental medicine.

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.

S. Armstrong, A. Ferrando, J. Teruya-Feldstein, 2015, Blood.

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis.

R. Levine, N. Bhagwat, M. Kleppe, 2014, Blood.